F2 and early-onset autosomal dominant Alzheimer disease: In a double-blind, placebo-controlled trial investigating EGb 761® in patients with Alzheimer’s disease, prothrombin time, activated partial thromboplastin time, international normalized ratio, and bleeding time were measured at baseline and after 6 and 26 weeks of treatment (Kloft and Hoerr, 2021).